- Conditions
- Resectable Non-Small Cell Lung Cancer
- Interventions
- Adagrasib, Adagrasib/Nivolumab
- Drug · Combination Product
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, Brain Tumors
- Interventions
- Marqibo
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
- Drug · Procedure
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 38
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 28 more
- Conditions
- Nausea and Vomiting Post-foregut Surgery
- Interventions
- Reletex, IV ondansetron 4 mg q 6 hours for a total of 4 doses, IV promethazine 25 mg q 6 hours prn, Elixir promethazine 25 mg q 6 hours prn after discharge
- Device · Drug
- Lead sponsor
- Kyle A Perry
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab, IMC-CS4
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Headache
- Interventions
- Metoclopramide, Diphenhydramine, Codeine
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 16 Years to 50 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Myeloma
- Interventions
- Cyclophosphamide, Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Staphylococcus Aureus Bacteremia
- Interventions
- Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Advanced Solid Tumors
- Interventions
- ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel
- Biological · Drug
- Lead sponsor
- AskGene Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Non Small Cell Lung Cancer Stage
- Interventions
- Hypo-Fractionation, Standard-Fractionation
- Radiation
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Kansas City, Kansas • Overland Park, Kansas • Topeka, Kansas + 3 more
- Conditions
- HIV Infections
- Interventions
- VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
- Biological · Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more
- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
- Interventions
- SON-DP
- Drug
- Lead sponsor
- Qurgen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more
- Conditions
- Glioblastoma, Brain Tumor, GBM
- Interventions
- Pembrolizumab, Vorinostat, Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Spine Surgery
- Interventions
- Lidocaine, placebo
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- High Grade Glioma
- Interventions
- O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 10 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more
- Conditions
- Ileus, Gastrointestinal Dysfunction
- Interventions
- Alvimopan
- Drug
- Lead sponsor
- Scott Steele
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery
- Other · Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Houston, Texas
- Conditions
- Inflammatory Breast Cancer (IBC)
- Interventions
- Ruxolitinib, Paclitaxel, Doxorubicin, Cyclophosphamide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Durham, North Carolina + 1 more
- Conditions
- Fractures, Bone, Fractures, Closed, Radius Fracture Distal
- Interventions
- Dexamethasone, Methylprednisolone, Standard of Care
- Drug · Other
- Lead sponsor
- Indiana Hand to Shoulder Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- La Jolla, California • Orange, California • Stanford, California + 21 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- Recombinant Interferon Alfa-2b, Rintatolimod
- Biological · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Solid Tumor
- Interventions
- Doppler ultrasound, Long Ensemble Angular-coherence Doppler [LEAD] ultrasound, Contrast-enhanced ultrasound (CEUS)
- Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington